| Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1. | Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1.
Hou W, Watson C, Cecconie T, Bolaki MN, Brady JJ, Lu Q, Gatto GJ Jr, Day TA., Free PMC Article | 07/23/2024 |
| Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome. | Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome.
Dutta T, Sasidharan K, Ciociola E, Pennisi G, Noto FR, Kovooru L, Kroon T, Lindblom A, Du Y, Pirmoradian M, Wallin S, Mancina RM, Lindén D, Romeo S. | 04/30/2024 |
| mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes. | mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.
Jones AK, Bajrami B, Campbell MK, Erzurumluoglu AM, Guo Q, Chen H, Zhang X, Zeveleva S, Kvaskoff D, Brunner AD, Muller S, Gathey V, Dave RM, Tanner JW, Rixen S, Struwe MA, Phoenix K, Klumph KJ, Robinson H, Veyel D, Muller A, Noyvert B, Bartholdy BA, Steixner-Kumar AA, Stutzki J, Drichel D, Omland S, Sheehan R, Hill J, Bretschneider T, Gottschling D, Scheidig AJ, Clement B, Giera M, Ding Z, Broadwater J, Warren CR., Free PMC Article | 04/18/2024 |
| Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse. | Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse.
Smagris E, Shihanian LM, Mintah IJ, Bigdelou P, Livson Y, Brown H, Verweij N, Hunt C, Johnson RO, Greer TJ, Hartford SA, Hindy G, Sun L, Nielsen JB, Halasz G, Lotta LA, Murphy AJ, Sleeman MW, Gusarova V., Free PMC Article | 03/19/2024 |
| Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1. | Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1.
Wu M, Tie M, Hu L, Yang Y, Chen Y, Ferguson D, Chen Y, He A., Free PMC Article | 02/27/2024 |
| MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery. | MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery.
Kalinowski P, Smyk W, Nowosad M, Paluszkiewicz R, Michałowski Ł, Ziarkiewicz-Wróblewska B, Weber SN, Milkiewicz P, Lammert F, Zieniewicz K, Krawczyk M., Free PMC Article | 01/11/2023 |
| Association of MARC1, ADCY5, and BCO1 Variants with the Lipid Profile, Suggests an Additive Effect for Hypertriglyceridemia in Mexican Adult Men. | Association of MARC1, ADCY5, and BCO1 Variants with the Lipid Profile, Suggests an Additive Effect for Hypertriglyceridemia in Mexican Adult Men.
Rivera-Paredez B, Aparicio-Bautista DI, Argoty-Pantoja AD, Patiño N, Flores Morales J, Salmerón J, León-Reyes G, Velázquez-Cruz R., Free PMC Article | 10/22/2022 |
| Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. | Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA, Adams LA, Alisi A, Anstee QM, Crudele A, Draijer LG, Furse S, Hengstler JG, Jenkins B, Karnebeek K, Kelly DA, Koot BG, Koulman A, Meierhofer D, Melton PE, Mori TA, Snowden SG, van Mourik I, Vreugdenhil A, Wiegand S, Mann JP, EU‐PNAFLD investigators., Free PMC Article | 07/30/2022 |
| A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes. | A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes.
Schneider CV, Schneider KM, Conlon DM, Park J, Vujkovic M, Zandvakili I, Ko YA, Trautwein C, Center R, Carr RM, Strnad P, Thaiss CA, Rader DJ., Free PMC Article | 05/7/2022 |
| MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis. | MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis.
Janik MK, Smyk W, Kruk B, Szczepankiewicz B, Górnicka B, Lebiedzińska-Arciszewska M, Potes Y, Simões ICM, Weber SN, Lammert F, Więckowski MR, Milkiewicz P, Krawczyk M., Free PMC Article | 01/29/2022 |
| Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. | Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1.
Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, Irving W, Forrest E, Pedergnana V, Goldberg D, Aspinall E, Barclay S, Hayes PC, Dillon J, Nischalke HD, Lutz P, Spengler U, Fischer J, Berg T, Brosch M, Eyer F, Datz C, Mueller S, Peccerella T, Deltenre P, Marot A, Soyka M, McQuillin A, Morgan MY, Hampe J, Stickel F. | 04/17/2021 |
| identification of a series of additional MARC1 alleles that also associated with lower cholesterol levels, liver enzyme levels and reduced risk of cirrhosis, suggesting that deficiency of the MARC1 enzyme may lower blood cholesterol levels and protect against cirrhosis | A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease.
Emdin CA, Haas ME, Khera AV, Aragam K, Chaffin M, Klarin D, Hindy G, Jiang L, Wei WQ, Feng Q, Karjalainen J, Havulinna A, Kiiskinen T, Bick A, Ardissino D, Wilson JG, Schunkert H, McPherson R, Watkins H, Elosua R, Bown MJ, Samani NJ, Baber U, Erdmann J, Gupta N, Danesh J, Saleheen D, Chang KM, Vujkovic M, Voight B, Damrauer S, Lynch J, Kaplan D, Serper M, Tsao P, Million Veteran Program, Mercader J, Hanis C, Daly M, Denny J, Gabriel S, Kathiresan S., Free PMC Article | 07/25/2020 |
| Functional characteristics of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians were determined. | Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians.
Ott G, Reichmann D, Boerger C, Cascorbi I, Bittner F, Mendel RR, Kunze T, Clement B, Havemeyer A. | 11/8/2014 |
| human mARC-1 and mARC-2 are capable of catalyzing reduction of nitrite to NO through reaction with its molybdenum cofactor | Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2.
Sparacino-Watkins CE, Tejero J, Sun B, Gauthier MC, Thomas J, Ragireddy V, Merchant BA, Wang J, Azarov I, Basu P, Gladwin MT., Free PMC Article | 06/21/2014 |
| Data indicate that mitochondrial amidoxime reducing components 1 and 2 together with the electron transport proteins NADH-cytochrome b5 reductase (CYB5R) and cytochrome b5 (CYB5) catalyze the reduction of N-hydroxylated compounds such as amidoximes. | The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells.
Plitzko B, Ott G, Reichmann D, Henderson CJ, Wolf CR, Mendel R, Bittner F, Clement B, Havemeyer A., Free PMC Article | 09/28/2013 |
| The transmembrane domain of mARC1 shown to be sufficient for mitochondrial targeting and the N-terminal targeting signal to function as a supportive receptor for the outer mitochondrial membrane. | The mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane.
Klein JM, Busch JD, Potting C, Baker MJ, Langer T, Schwarz G., Free PMC Article | 02/16/2013 |
| Chlamydomonas reinhardtii ARC has a Zn-dependent activity and protein partners similar to human MARC1 and MARC2. | The Chlamydomonas reinhardtii molybdenum cofactor enzyme crARC has a Zn-dependent activity and protein partners similar to those of its human homologue.
Chamizo-Ampudia A, Galvan A, Fernandez E, Llamas A., Free PMC Article | 02/18/2012 |
| results provide the first hints that mARC might be involved in mitochondrial N(omega)-hydroxy-L-arginine reduction and could be of physiological significance in affecting endogenous nitric oxide levels | Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).
Kotthaus J, Wahl B, Havemeyer A, Kotthaus J, Schade D, Garbe-Schönberg D, Mendel R, Bittner F, Clement B. | 01/29/2011 |
| Arc1(MOSC-1) and Arc2(MOSC-2) proteins are monomeric in their active forms. | Biochemical and spectroscopic characterization of the human mitochondrial amidoxime reducing components hmARC-1 and hmARC-2 suggests the existence of a new molybdenum enzyme family in eukaryotes.
Wahl B, Reichmann D, Niks D, Krompholz N, Havemeyer A, Clement B, Messerschmidt T, Rothkegel M, Biester H, Hille R, Mendel RR, Bittner F., Free PMC Article | 01/1/2011 |
| Observational study of gene-disease association. (HuGE Navigator) | Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression.
Hendrickson SL, Lautenberger JA, Chinn LW, Malasky M, Sezgin E, Kingsley LA, Goedert JJ, Kirk GD, Gomperts ED, Buchbinder SP, Troyer JL, O'Brien SJ., Free PMC Article | 12/5/2010 |
| molybdoprotein mARC1 is involved in the activation of N-hydroxylated prodrugs. | The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
Gruenewald S, Wahl B, Bittner F, Hungeling H, Kanzow S, Kotthaus J, Schwering U, Mendel RR, Clement B. | 01/21/2010 |